Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2009

UCB Taps Proteros for Structure-Based Drug Discovery

  • UCB is employing Proteros biostructures to support structure-based discovery of small molecule drugs. Proteos will receive research fees and milestones.

    Initially, Proteros will leverage its expertise in gene-to-structure projects and its technologies to solve the 3-D structure of an undisclosed target together with its related proteins.

    After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of confirming the binding modes to the proteins. This will facilitate medicinal chemistry research and optimization of small molecules, the companies say.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »